GMP – Page 61 – Pharma.Tips

Extended cleaning duration during equipment changeover – inspection-ready cleaning optimization

Optimizing Cleaning Duration during Equipment Changeover: A Practical Guide for Pharma Professionals In pharmaceutical manufacturing, extended cleaning duration during equipment changeover is a significant concern that can lead to production…

PQ dossier deficiency during dossier submission – preventing PQ suspension

Managing PQ Dossier Deficiencies: A Comprehensive Action Plan to Prevent Submission Issues Deficiencies in the PQ dossier during submission can lead to significant delays and potential suspensions in product approval.…

PQ dossier deficiency during WHO PQ assessment – preventing PQ suspension

Actionable Playbook for Addressing PQ Dossier Deficiency in WHO Assessments Ensuring compliance during a WHO PQ assessment is crucial for pharmaceutical companies aiming for international recognition. However, deficiencies in the…

CAPA effectiveness doubted during dossier submission – preventing PQ suspension

Addressing Concerns About CAPA Effectiveness During Dossier Submissions for WHO Prequalification In the world of pharmaceutical manufacturing, ensuring compliance with Good Manufacturing Practices (GMP) is paramount. A frequent challenge faced…

Ineffective cleaning validation scope during equipment changeover – validated efficiency improvement

Enhancing Cleaning Validation Scope to Address Ineffectiveness During Equipment Changeover In the fast-paced world of pharmaceutical manufacturing, ineffective cleaning validation during equipment changeover can lead to serious quality risks and…

Deviation history questioned during variation management – preventing PQ suspension

Managing Deviation Histories During Variation Management to Prevent PQ Suspensions In the highly regulated pharmaceutical environment, maintaining a robust deviation history is critical, particularly when navigating variation management. Organizations may…

Stability data gaps during variation management – preventing PQ suspension

Addressing Stability Data Gaps During Variation Management to Prevent PQ Suspension One common but critical issue faced by pharmaceutical manufacturers during variation management is the identification and resolution of stability…

Deviation history questioned during requalification – preventing PQ suspension

Addressing Deviation History During Requalification to Prevent PQ Suspension In the dynamic environment of pharmaceutical manufacturing, the questioning of deviation history during requalification for WHO Prequalification (PQ) can present significant…

Ineffective cleaning validation scope during multi-product campaigns – validated efficiency improvement

Enhancing Cleaning Validation for Multi-Product Campaigns: Solutions for Ineffective Scope In the pharmaceutical manufacturing landscape, ensuring compliance during multi-product campaigns can often present challenges, particularly regarding cleaning validation. Ineffective cleaning…

Manufacturing site not PQ-ready during WHO PQ assessment – CAPA expectations for PQ approval

Ensuring Your Manufacturing Site is PQ-Ready for WHO Assessments: A Comprehensive Playbook Manufacturing sites face stringent requirements during WHO Prequalification (PQ) assessments, and any deviation can lead to a determination…

PQ dossier deficiency during variation management – PQ assessment risk and mitigation

Mitigating Deficiencies in PQ Dossier During Variation Management Managing variations within the pharmaceutical manufacturing space is fraught with challenges, particularly when it comes to maintaining compliance with Prequalification (PQ) requirements…

API change not reported during requalification – documentation gaps reviewers flag

Addressing API Changes Not Reported During Requalification: A Practical Playbook In the pharmaceutical manufacturing landscape, the consequences of undocumented Active Pharmaceutical Ingredient (API) changes during requalification processes can be significant.…